Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

For his second term in the House of Representatives, Quezon 4th district Rep. Keith Micah “Atty. Mike” Tan has decided to pursue digital and ...

The lab's 25 or so full-time employees were put on administrative leave on March 27, forcing it to shut down operations.

See related article at A crisis of communicable diseases is unfolding in North America, just as Canada’s health systems’ responses are being hampered by the dismantling of public health and research ...